Will This Efficacy Stumble Hurt Pfizer?
All of the currently authorized coronavirus vaccines are highly efficacious -- and have even proven their power against the many variants that have gained ground since the start of the year. Pfizer (NYSE: PFE) and partner BioNTech have boasted particularly strong efficacy data, and the most recent follow-up from the companies' phase 3 trials showed 91.3% effectiveness.
Just recently, however, data out of Israel suggests the Pfizer vaccine may not work as well all of the time against the Delta variant. That's the coronavirus strain that began in India and has since become dominant in other parts of the world -- including the U.S. state of California. Let's take a look at the latest data and see whether it will upend Pfizer's position in the vaccine space.
Image source: Getty Images.
Source Fool.com
